Infectious diseases still remain one of the biggest challenges for human health. In order to
gain a better understanding of the pathogenesis of infectious diseases and develop effective …

Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis
control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of …

Schistosoma haematobium is the etiologic agent for urogenital schistosomiasis, a major
source of morbidity and mortality for more than 112 million people worldwide. Infection with …

Inflammation is likely a critical underlying etiology in many forms of severe pulmonary
hypertension (PH), and schistosomiasis-associated PH, one of the most common causes of …

Background Praziquantel (PZQ) is the mainstay of schistosomiasis control and has been
successfully used for decades. However, its mechanism of action is not fully understood …

Background Praziquantel is the drug of choice in preventive chemotherapy targeting
schistosomiasis. Increasing large-scale administration of praziquantel requires monitoring of …

Background Schistosoma haematobium, the helminth causing urogenital schistosomiasis, is
a known bladder carcinogen. Despite the causal link between S. haematobium and bladder …

Although great reductions in human schistosomiasis have been observed after praziquantel
(PZQ) mass drug administration (MDA), some individuals remain infected after multiple …

Successful metazoan parasitism, among many other factors, requires a supply of nutrients
and the removal of waste products. There is a prerequisite for a parasite-defined …

Spirocerca lupi is a parasitic nematode of canids that induces a myriad of clinical
manifestations in its host and, in 25% of infections, leads to the formation of sarcomas. The …